New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:36 EDTRGDORegado Biosciences announecs USPTO issues new patent to company
Regado Biosciences announced that the United States Patent and Trademark Office has issued an important patent that expands protection of Regado's core technology platform while broadening the range of aptamer-based therapies upon which Regado may base future products. Regado's current drug development programs, including its lead REG1 Anticoagulation System, consist of an aptamer-based pharmacologic drug paired with a specific control agent.
News For RGDO From The Last 14 Days
Check below for free stories on RGDO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
10:01 EDTRGDOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CSR (CSRE) downgraded to Hold from Buy at Jefferies... Celadon Group (CGI) downgraded to Equal Weight from Overweight at Stephens... Cree (CREE) downgraded to Hold from Buy at Summit Research... Crestwood Equity (CEQP) downgraded to Underweight from Equal Weight at Barclays... Intrepid Potash (IPI) downgraded to Sell from Hold at BGC Financial... JDSU (JDSU) downgraded to Neutral from Buy at B. Riley... King Digital (KING) downgraded to Equal Weight from Overweight at Barclays... Marin Software (MRIN) downgraded to Neutral from Buy at Goldman... Mosaic (MOS) downgraded to Sell from Hold at BGC Financial... Potash (POT) downgraded to Sell from Hold at BGC Financial... Regado Biosciences (RGDO) downgraded to Market Perform from Outperform at Cowen... Southern Company (SO) downgraded to Underweight from Equal Weight at Morgan Stanley... StarTek (SRT) downgraded to Equal Weight from Overweight at First Analysis... Tuniu (TOUR) downgraded to Neutral from Outperform at Credit Suisse.
06:15 EDTRGDORegado Biosciences downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
August 11, 2014
16:42 EDTRGDORegado Biosciences reports Q2 EPS (63c), consensus (51c)
Cash and cash equivalents at June 30, totaled $72.7M compared to $30.7M at December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use